Evidence map›Paper›PMID 28282490›Full record

ArticleInvestigative ophthalmology & visual science2017

Gene Augmentation Therapy for a Missense Substitution in the cGMP-Binding Domain of Ovine CNGA3 Gene Restores Vision in Day-Blind Sheep.

Elisha Gootwine, Mazen Abu-Siam, Alexey Obolensky, Alex Rosov, Hen Honig, Tali Nitzan, Andrey Shirak, Raaya Ezra-Elia, Esther Yamin, Eyal Banin and 4 more

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Gene Therapy for Achromatopsia.International journal of molecular sciences · 2024
    Review
  3. Canine and Feline Models of Inherited Retinal Diseases.Cold Spring Harbor perspectives in medicine · 2024
    Review
  4. Article
  5. Article
  6. Review
  7. Gene therapy in color vision deficiency: a review.International ophthalmology · 2021
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Retinal Cyclic Nucleotide-Gated Channels: From Pathophysiology to Therapy.International journal of molecular sciences · 2018
    Review
  16. Gene Therapy for Color Blindness.The Yale journal of biology and medicine · 2017
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Elisha GootwineAgricultural Research Organization, The Volcani Center, Rishon LeZion, Israel.
Mazen Abu-SiamAbu Siam Veterinary Clinic, Rahat, Israel.
Alexey ObolenskyDepartment of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Alex RosovAgricultural Research Organization, The Volcani Center, Rishon LeZion, Israel.
Hen HonigAgricultural Research Organization, The Volcani Center, Rishon LeZion, Israel.
Tali NitzanAgricultural Research Organization, The Volcani Center, Rishon LeZion, Israel.
Andrey ShirakAgricultural Research Organization, The Volcani Center, Rishon LeZion, Israel.
Raaya Ezra-EliaKoret School of Veterinary Medicine, Hebrew University of Jerusalem, Rehovot, Israel.
Esther YaminDepartment of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Eyal BaninDepartment of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Edward AverbukhDepartment of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
William W HauswirthDepartment of Ophthalmology, University of Florida, Gainesville, Florida, United States.
Ron OfriKoret School of Veterinary Medicine, Hebrew University of Jerusalem, Rehovot, Israel.
Eyal SeroussiAgricultural Research Organization, The Volcani Center, Rishon LeZion, Israel.
Agricultural Research Organization · ILHadassah Medical Center · ILHebrew University of Jerusalem · ILUniversity of Florida · US

Funding

rAAV-CNGB3 Gene Therapy for Achromatopsia: Translational Research StudiesR24EY022023 · NEI · UNIVERSITY OF FLORIDA · PI HAUSWIRTH, WILLIAM W · 2013 to 2017
$7.9M
NEI NIH HHS R24 EY022023
6 · The paper itself

Abstract

Purpose: Applying CNGA3 gene augmentation therapy to cure a novel causative mutation underlying achromatopsia (ACHM) in sheep. Methods: Impaired vision that spontaneously appeared in newborn lambs was characterized by behavioral, electroretinographic (ERG), and histologic techniques. Deep-sequencing reads of an affected lamb and an unaffected lamb were compared within conserved genomic regions orthologous to human genes involved in similar visual impairment. Observed nonsynonymous amino acid substitutions were classified by their deleteriousness score. The putative causative mutation was assessed by producing compound CNGA3 heterozygotes and applying gene augmentation therapy using the orthologous human cDNA. Results: Behavioral assessment revealed day blindness, and subsequent ERG examination showed attenuated photopic responses. Histologic and immunohistochemical examination of affected sheep eyes did not reveal degeneration, and cone photoreceptors expressing CNGA3 were present. Bioinformatics and sequencing analyses suggested a c.1618G>A, p.Gly540Ser substitution in the GMP-binding domain of CNGA3 as the causative mutation. This was confirmed by genetic concordance test and by genetic complementation experiment: All five compound CNGA3 heterozygotes, carrying both p.Arg236* and p.Gly540Ser mutations in CNGA3, were day-blind. Furthermore, subretinal delivery of the intact human CNGA3 gene using an adeno-associated viral vector (AAV) restored photopic vision in two affected p.Gly540Ser homozygous rams. Conclusions: The c.1618G>A, p.Gly540Ser substitution in CNGA3 was identified as the causative mutation for a novel form of ACHM in Awassi sheep. Gene augmentation therapy restored vision in the affected sheep. This novel mutation provides a large-animal model that is valid for most human CNGA3 ACHM patients; the majority of them carry missense rather than premature-termination mutations.

Indexed as

MutationAnimalsAnimals, NewbornCarrier ProteinsColor Vision DefectsCyclic Nucleotide-Gated Cation ChannelsDisease Models, AnimalDNADNA Mutational AnalysisElectroretinographyFemaleGenetic TherapyGenotypeHomozygoteImmunohistochemistryIntracellular Signaling Peptides and ProteinsCarrier ProteinsCNGA3 protein, humancyclic GMP-binding proteinCyclic Nucleotide-Gated Cation ChannelsDNAIntracellular Signaling Peptides and Proteins

Identifiers

PMID28282490
PMCPMC5361581
OpenAlexW2592578002

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.